Molly Bowen

CRS:

BJMC

Role:

Communications

Position:

Communications Associate

Email:

molly.bowen@jhmi.edu

Phone:

410-955-9948

Molly Bowen is Communications Associate at the Johns Hopkins Center for Clinical Global Health Education (CCGHE). She establishes and maintains systems for information management, and devises strategies, develops content, and manages production and workflow for organizational reporting, donor relations, media outreach, marketing and promotional materials, and the CCGHE website. She also is charged with communications for the Baltimore-Washington-India Clinical Trials Unit.

Prior to joining CCGHE in March 2015, Molly worked for more than 15 years with Dr. D.A. Henderson, first joining the Johns Hopkins Center for Civilian Biodefense Studies in 1999, and moving with the group in 2003 to found the UPMC Center for Health Security. As the first non-faculty member hired, Molly established administrative, finance, and communications functions for the organization, and served for 10 years as Senior Communications Specialist. Prior to that position, she worked for 9 years with ORBIS Associates, non-profit American Indian owned and managed educational consulting firm in Washington, DC.

She has a BA in American Studies from Keene State College, Keene, New Hampshire.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More